Date | Title | Description |
31.12.2024 | Alphamab Oncology's Bold Steps in Cancer Treatment: A New Era of Bispecific Antibody-Drug Conjugates | In the relentless battle against cancer, innovation is the sword that cuts through despair. Alphamab Oncology, a biopharmaceutical company based in Suzhou, China, is wielding this sword with precision. Recently, the company announced signif... |
30.12.2024 | Alphamab Oncology Announced Anti-HER2 Bispecific ADC JSKN003 Received Approval from CDE to Initiate a Phase III Clinical Study for Ovarian Cancer | SUZHOU, China, Dec. 27, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 has received approval from the Center for Drug Evaluation (CDE) of the National M... |
26.12.2024 | IND Application for a Phase I/II Clinical Study of Anti-HER2 Bispecific ADC Subcutaneous Co-formulation JSKN033 was Approved | SUZHOU, China, Dec. 26, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that a phase I/II clinical trial (Study ID: JSKN033-102) of JSKN033, a high-concentration subcutaneous co-formulation consisting of anti-HER2 bis... |
15.12.2024 | Aurobindo, Glenmark, Zydus recall products in US over manufacturing issues | Drug makers Aurobindo Pharma, Glenmark and Zydus are recalling products in the US market due to manufacturing issues, according to the US health regulator.
As per the latest Enforcement Report of US Food and Drug Administration (USFDA), Aur... |
13.12.2024 | Alphamab Oncology Presented the Phase II Clinical Data of KN046 in Combination with Axitinib for the Treatment of Advanced NSCLC at ESMO IO Congress 2024 | SUZHOU, China, Dec. 13, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the latest clinical data from a phase II clinical study on PD-L1/CTLA-4 bispecific antibody KN046 in combination with axitinib as first-line... |
11.12.2024 | Oriola renews operating model and management team to accelerate strategy execution | Oriola renews operating model and management team to accelerate strategy execution
Wed, Dec 11, 2024 08:15 CET Report this content
Oriola Corporation Stock Exchange Release 11 December 2024 at 9:15 a.m. EET Oriola renews operating model and... |
11.11.2024 | Late-Breaking Abstract! Alphamab Oncology Presented the Latest Clinical Data of Anti-HER2 bispecific ADC Subcutaneous Co-formulation JSKN033 at SITC 2024 | SUZHOU, China, Nov. 11, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the results of the first-in-human clinical study of JSKN033, a high-concentration subcutaneous co-formulation consisting of anti-HER2 bispec... |
28.10.2024 | Japan's Political Storm: Markets Brace for Impact | Japan stands at a crossroads. The recent general election has sent shockwaves through the political landscape, leaving uncertainty in its wake. The ruling coalition, led by Prime Minister Shigeru Ishiba, is poised to lose its parliamentary ... |
25.10.2024 | Morning Bid: Markets becalmed, eyes on Japan | Asian MarketsMorning Bid: Markets becalmed, eyes on Japan
By Jamie McGeeverOctober 24, 20249:48 PM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
CommentaryBy Jamie McGeever
Media members observe ... |
01.09.2024 | Trade Spotlight: How should you trade UPL, Glenmark Pharma, GSPL, Radico Khaitan, RVNL, and others on Monday? | Stocks Picks for Short Term
Trade Watchlist Portfolio
Message
Set Alert
livebselivenselive
Volume
Todays L/H
More
×
The benchmark indices continued their record-high streak despite volatility on August 30, with 1,366 shares advancing and 98... |
28.08.2024 | GoComet Named Top Employer at 2024 GCC Workplace Awards | Ayush Lodhi, Chief Technology Officer - GoComet accepting the 2024 GCC Workplace Award in the category of Employee Rewards and Recognition
GoComet Honoured as a Top Employer Alongside ABB, Sanofi, G2, and Hitachi Energy India at the 2024 GC... |
21.08.2024 | Glenmark and SalioGen: A New Era in Ophthalmic Treatments | In the bustling world of pharmaceuticals and biotechnology, two companies are making waves in the ophthalmic sector. Glenmark Therapeutics Inc. and SalioGen Therapeutics are not just players; they are pioneers. Their recent announcements re... |
19.08.2024 | Glenmark Therapeutics Inc., USA launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1% (OTC) | MAHWAH, N.J., Aug. 19, 2024 /PRNewswire/ -- Glenmark Therapeutics Inc., USA (Glenmark) is pleased to announce it has launched1 Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1% (OTC); compare to the active ingredient in Pataday®2 Twic... |
16.08.2024 | Alphamab Oncology Reports 2024 Interim Results and Business Highlights | SUZHOU, China, Aug. 16, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) reported interim financial results for the six months ended June 30, 2024 and highlighted recent business progress.
Financial Summary
For the six months en... |
29.05.2024 | Health secy highlights India's achievements, future goals at WHO assembly | - |
27.05.2024 | Pharma stocks in focus; Astrazeneca, Glenmark, Divi's, Torrent soar upto 9% | - |
21.05.2024 | Expect formulations biz to outpace API biz: Biocon Group CEO Peter Bains | - |
17.05.2024 | Pharma major Glenmark gets USFDA nod for generic ophthalmic solution | - |
17.05.2024 | Indian pharma firms supplied 47% of all generic prescriptions in US in 2022 | - |
08.05.2024 | Dr Reddy's Labs slumps 5% as brokerages give 'Reduce' call post Q4 earnings | - |
05.05.2024 | Cipla, Glenmark recall drugs from US over manufacturing issues: USFDA | - |
04.05.2024 | Productivity loss due to oral cancer in India in 2022 at $5.6 bn: Study | - |
02.05.2024 | India, New Zealand look to boost collaboration in pharma, digital trade | - |
01.05.2024 | Mizoram sees alarming surge in TB deaths, 108 succumb to disease in 2023 | - |
29.04.2024 | Glenmark Pharma receives USFDA nod for generic anti-inflammatory drug | - |
14.04.2024 | Glenmark recalls 6,528 bottles of blood pressure drug in US | Glenmark Pharmaceuticals is recalling 6,528 bottles of a medication used to treat high blood pressure in the American market due to failed dissolution specifications, the US health regulator said.
The US-based arm of the Mumbai-headquartere... |
29.03.2024 | Alphamab Oncology Reports Full Year 2023 Financial Results and Business Highlights | SUZHOU, China, March 29, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) reported financial results for the full year ended December 31, 2023 and highlighted recent progress and upcoming milestones.
Dr. Ting Xu, Chairman and CE... |
07.03.2024 | SpiceJet resolves Rs 413 cr dispute with Echelon Ireland Madison One | After Cross Ocean Partners and Celestial Aviation, SpiceJet has announced the successful resolution of a dispute with Echelon Ireland Madison One Ltd., marking a significant milestone for the airline. The settlement, valued at $49.8 million... |
18.07.2022 | Chemill Launches Clinically Proven Nitric Oxide Nasal Spray – VirX™ in Hong Kong A Safe Antiviral Treatment Killing 99.9% Virus in 2 Minutes to Fight the Pandemic Virus | Clinical Trials in Canada, India and U.K. Confirm the Efficacy
HONG KONG SAR – Media OutReach – 18 July 2022 – Chemill Pharma Ltd, today announced the launch of a clinically proven and safe nitric oxide nasal spray (NONS), under the brand n... |
09.02.2022 | Glenmark and SaNOtize announce positive Results from Phase 3 Clinical Trial of NONS (FabiSpray®) in Non-Hospitalized Adult Indian Patients with COVID-19 | Phase 3 trial in India met the key endpoints and demonstrated reduction of viral load of 94% in 24 hours and 99% in 48 hours.
NONS was safe and well tolerated in COVID-19 patients.
Glenmark received manufacturing and marketing approval from... |
20.01.2022 | Glenmark Specialty S.A. and Lotus International Pte. Ltd. enter into Exclusive Licensing Agreement for commercializing Ryaltris (TM) Nasal Spray in Singapore, Hong Kong and Vietnam | Under the terms of the agreement, Glenmark will be responsible for the manufacture and supply of Ryaltris™, while Lotus International Pte. Ltd. will be responsible for the commercialization of Ryaltris™ (subject to receipt of regulatory app... |
20.01.2022 | Glenmark Pharmaceuticals : Quarter 3 Oct 01 - Dec 31 View / Download | Name of Listed Entity : GLENMARK PHARMACEUTICALS LIMITED
Scrip Code/Name of Scrip/Class of Security: 532296, GLENMARK, EQUITY SHARES
Share Holding Pattern Filed under: Reg. 31(1)(a)/Reg.31(1)(b)/Reg.31(1)(c)
if under 31(1)(b) then indicate ... |
14.01.2022 | Glenmark Specialty S.A. (Switzerland) receives NDA Approval by the United States Food and Drug Administration (FDA) for Ryaltris™ Nasal Spray for the Treatment of Symptoms of Seasonal Allergic Rhiniti... | MUMBAI, India and MAHWAH, N.J., Jan. 14, 2022 /PRNewswire/ -- Glenmark Pharmaceuticals Limited, a research-led, global integrated pharmaceutical company announced that its fully owned subsidiary Glenmark Specialty S.A. (Switzerland), receiv... |
15.12.2021 | Glenmark arm nets Rs 180 cr in licensing deal for autoimmune antibody | Glenmark subsidiary Ichnos Sciences, a biotechnology company that develops biologics in oncology and autoimmune diseases, has licensed the commercialisation rights of a monoclonal antibody for autoimmune diseases to Almirall for €20.8 milli... |
21.10.2021 | Glenmark Pharmaceuticals : Quarter 2 Jul 01 - Sept 30 View / Download | Name of Listed Entity : GLENMARK PHARMACEUTICALS LIMITED
Scrip Code/Name of Scrip/Class of Security: 532296, GLENMARK, EQUITY SHARES
Share Holding Pattern Filed under: Reg. 31(1)(a)/Reg.31(1)(b)/Reg.31(1)(c)
if under 31(1)(b) then indicate ... |
11.10.2021 | Glenmark Pharmaceuticals : launches Tavulus® for COPD treatment in Spain, becoming one of the first companies to launch a bioequivalent version of the dry powder inhaler | Press Release For immediate distribution
Glenmark launches Tavulus® for COPD treatment in Spain, becoming one of the first companies to launch a bioequivalent version of the dry powder inhaler
Tiotropium Bromide dry powder inhaler (DPI) is ... |
11.10.2021 | General Announcement::Glenmark launches Tavulus for COPD treatment in Spain becoming one of the first companies to launch | October 11, 2021
To,
SINGAPORE EXCHANGE SECURITIES
TRADING LIMITED
11 North Buona Vista Drive,
#06-07 The Metropolis Tower 2,
Singapore - 138589
Dear Sir,
Sub: Glenmark launches Tavulus® for COPD treatment in Spain, becoming one of the firs... |
30.09.2021 | Glenmark Pharmaceuticals : receives marketing approval for Ryaltris®, an innovative combination nasal spray, in 13 countries across the EU and UK | Press Release For immediate distribution
Glenmark receives marketing approval for Ryaltris®, an innovative combination nasal
spray, in 13 countries across the EU and UK
Ryaltris® is a fixed dose combination nasal spray that combines an anti... |
21.09.2021 | Glenmark Pharmaceuticals : receives ANDA approval for Clindamycin Phosphate Foam, 1% | Press Release For Immediate Release
Glenmark Pharmaceuticals receives ANDA approval for
Clindamycin Phosphate Foam, 1%
Mumbai, India, September 21, 2021: Glenmark Pharmaceuticals Ltd. (Glenmark) has received final approval by the United Sta... |
02.08.2021 | Glenmark Pharmaceuticals : inks agreement with Canadian biotech SaNOtize to commercialize Nitric Oxide Nasal Spray for COVID-19 treatment in India and other Asian markets | Press Release For immediate distribution
Glenmark inks agreement with Canadian biotech SaNOtize to commercialize Nitric Oxide Nasal Spray for COVID-19 treatment in India and other Asian markets
Nitric oxide (NO) has antimicrobial properties... |
21.07.2021 | Glenmark Pharmaceuticals subsidiary Glenmark Life Sciences to raise ₹1,060 crore through IPO | Glenmark Life Sciences will reportedly launch its IPO on July 27.
Parent company Glenmark Pharmaceuticals will reduce its stake in the company and make an offer for sale of up to 63 lakh shares.
The stock will reportedly be listed on August... |
23.06.2021 | Glenmark Pharmaceuticals : receives ANDA approval for Arformoterol Tartrate Inhalation Solution, 15 mcg/2 mL, Unit-Dose Vials | Press Release For Immediate Release
Glenmark Pharmaceuticals receives ANDA approval for
Arformoterol Tartrate Inhalation Solution, 15 mcg/2 mL, Unit-Dose Vials
Mumbai, India; June 23, 2021: Glenmark Pharmaceuticals Ltd (Glenmark) has receiv... |
15.06.2021 | GLENMARK PHARMACEUTICALS LIMITED
Glenmark Pharmaceuticals : launches Tiogiva®, becoming one of the first companies in the UK to launch a bioequivalent version of Tiotropium Bromide dry powder inhaler... | Press Release For Immediate Release
Glenmark launches Tiogiva®, becoming one of the first companies in the UK to launch a bioequivalent version of Tiotropium Bromide dry powder inhaler
Glenmark has launched Tiotropium Bromide Dry Powder Inh... |
04.06.2021 | GLENMARK PHARMACEUTICALS LIMITED
Glenmark Pharmaceuticals receives ANDA approval for Theophylline Extended-Release Tablets, 300 mg and 450 mg: Granted competitive generic therapy (CGT) designation an... | Press Release For Immediate Release
Glenmark Pharmaceuticals receives ANDA approval for Theophylline Extended-Release Tablets, 300 mg and 450 mg:
Granted competitive generic therapy (CGT) designation and is eligible for
180 days of CGT excl... |
01.06.2021 | GLENMARK PHARMACEUTICALS LIMITED
Glenmark Pharmaceuticals : launches Rufinamide Tablets USP, 200 mg and 400 mg | Press Release For Immediate Release
Glenmark Pharmaceuticals launches
Rufinamide Tablets USP, 200 mg and 400 mg
Mumbai, India, June 1, 2021: - Glenmark Pharmaceuticals Limited (Glenmark) has launched Rufinamide Tablets USP, 200 mg and 400 m... |
24.05.2021 | GLENMARK PHARMACEUTICALS LIMITED
Glenmark Pharmaceuticals : receives ANDA approval for Icatibant Injection, 30 mg/3 mL (10 mg/mL) Single-Dose Prefilled Syringe | Press Release For Immediate Release
Glenmark Pharmaceuticals receives ANDA approval for
Icatibant Injection, 30 mg/3 mL (10 mg/mL) Single-Dose Prefilled Syringe
Mumbai, India, May 24, 2021: - Glenmark Pharmaceuticals Limited (Glenmark) has ... |
03.05.2021 | GLENMARK PHARMACEUTICALS LIMITED
Glenmark Pharmaceuticals : launches Ryaltris®-AZ at an affordable price in India | Press release For immediate distribution
Glenmark launches Ryaltris®-AZ at an affordable price in India
Glenmark becomes the first company in the world to launch Ryaltris®-AZ as a novel fixed dose combination of Mometasone furoate 50 mcg + ... |
12.04.2021 | GLENMARK PHARMACEUTICALS LIMITED
Glenmark Pharmaceuticals : Announcement by Glenmark Pharmaceuticals Limited (the “Company”) of the results of the Proposal in respect of its U.S.$200,000,000 2.00 per... | 12 April 2021 To, To,
Dy. General Manager The Manager - Listing
Department of Corporate Services, National Stock Exchange of India Ltd.,
BSE Ltd. Plot No. C/1, G Block,
Phiroze Jeejeebhoy Towers Bandra Kurla Complex,
Dalal Street, Fort, Mum... |
10.04.2021 | Glenmark Pharmaceuticals : QUARTER 4 Jan1-Mar31 View / Download | Name of Listed Entity: GLENMARK PHARMACEUTICALS LIMITED
Scrip Code/Name of Scrip/Class of Security:532296,GLENMARK,EQUITY SHARES
Share Holding Pattern Filed under: Reg. 31(1)(a)/Reg.31(1)(b)/Reg.31(1)(c)
if under 31(1)(b) then indicate the ... |
27.03.2021 | GLENMARK PHARMACEUTICALS LIMITED
Glenmark Pharmaceuticals : Announcement of the Results of the Offer in respect of U.S.$200,000,000 2.00 per cent. Resettable Onward Starting Equity-linked Securities ... | March 27, 2021
To, To,
Dy. General Manager The Manager - Listing
Department of Corporate Services, National Stock Exchange of India Ltd.,
BSE Ltd. Plot No. C/1, G Block,
Phiroze Jeejeebhoy Towers Bandra Kurla Complex,
Dalal Street, Fort, Mu... |
24.03.2021 | GLENMARK PHARMACEUTICALS LIMITED
Glenmark Pharmaceuticals receives ANDA approval for Chlorpromazine Hydrochloride Tablets USP, 10 mg, 25 mg, 50 mg, 100 mg, and 200 mg: Granted competitive generic the... | Press Release For Immediate Release
Glenmark Pharmaceuticals receives ANDA approval for
Chlorpromazine Hydrochloride Tablets USP, 10 mg, 25 mg, 50 mg, 100 mg, and 200 mg: Granted competitive generic therapy (CGT) designation and is eligible... |
23.03.2021 | Glenmark Pharmaceuticals gets $40-million Covid loan from IFC | World Bank Group lender’s loan is under its $8-billion credit-line Covid-19 facility
The International Finance Corporation on Tuesday said Mumbai-based Glenmark Pharmaceuticals has become the first Indian drug-maker to get a $40-million (ab... |
19.08.2019 | Glenmark launches Remogliflozin combo in India; GeneCentric Therapeutics buys Select ImmunoGenomics | → India’s Glenmark in April launched domestically a new SGLT2 inhibitor called Remogliflozin — marking the first-ever launch of the diabetes drug, which was partly developed by GSK $GSK. SGLT2 inhibitors, such as Forxiga, I... |
25.04.2018 | A new home for life sciences companies in the Canton of Vaud | |
12.03.2018 | Glenmark gets $15 m advance payment from Salix Pharma to upgrade plant | Glenmark Pharmaceuticals today said it has received $15 million (over Rs 65 crore) from Salix Pharmaceuticals Inc, USA, as an advance payment to upgrade its plant for production of Crofelemer, used for treating diarrhoea.
“This is as per an... |
12.03.2018 | Glenmark nets Rs 457 cr in 2010-11 on strong India, US sales | Buoyed by its performance in the Indian and American markets, drug-maker Glenmark Pharmaceuticals clocked a consolidated net profit of Rs 457 crore for the financial year ended March 31, 2011.
It had registered a consolidated net profit of ... |
24.11.2017 | Glenmark receives $5 m milestone payment from Sanofi | Glenmark Pharmaceuticals, through its Swiss subsidiary, has received $5 million (around ₹30.1 crore) milestone fee payment from French pharmaceutical company Sanofi SA, for its collaboration on a monoclonal antibody for chronic autoimmune d... |
18.04.2015 | Temasek to invest $151m in India’s Glenmark Pharma | Premium
Singapore state investment firm Temasek Holdings had picked up a 3.83% stake in India’s Glenmark Pharmaceuticals Ltd for $151 million, the latter said in a statement.
Continue reading this story with a subscription to DealStreetAsia... |
25.03.2014 | Glenmark receives $4 million from Forest Lab as research fee | --> |
07.11.2011 | Glenmark gets $5 mn payment from Sanofi-Aventis | Drug firm Glenmark Pharmaceuticals on Monday said it has received a payment of $5 million (over Rs 24 crore) from Sanofi-Aventis on completion of Phase I study of molecule ‘GRC 15300’ being developed for treatment of pain.
Glenmark Pharmace... |
05.02.2009 | Napo Pharm raises seed money for its anti-diarrheal drug | Napo Pharmaceuticals, a South San Francisco-based drug company, just closed a round of initial funding from Asset Management. The undisclosed sum is earmarked for its subsidiary Crofelemer Access Program Global, which makes an anti-diarrhea... |